Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point

Anticancer Research

Volumn 18, Issue 1 A, 1998, Pages 321-325

  Wang, Li Hong ^a   Okaichi, Kumio ^a   Ihara, Makoto ^a   Okumura, Yutaka ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticancer drugs; Chemotherapy; Mutant p53; Transfectant

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DOXORUBICIN; MUTANT PROTEIN; NIMUSTINE; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

BLEOMYCIN; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; MUTAGENESIS, SITE-DIRECTED; NIMUSTINE; OSTEOSARCOMA; POINT MUTATION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031923447     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Levine AJ, Momand J and Finlay CA: The p53 tumor suppresser gene. Nature 351: 453-456, 1991.
3. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW and O' Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
4. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P and Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157, 1994.
5. Vasey PA, Jones N, Jenkins S, Dive C and Brown R: Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Molecular Pharmacology 50: 1536-1540, 1996.
6. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
7. Hawkins DS, Demers GW and Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
8. Chen C and Okayama H: Hight-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology 7: 2745-2752, 1987
9. Okaichi K, Wang L, Ihara M, and Okumura Y, in preparation.
10. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
11. Lane DP: Cancer. A death in the life of p53. Nature 362: 786-787, 1993.
12. Lowe SW, Ruley HE, Jaeks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
13. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.